Hypertriglyceridemia

CHICAGO — In this Healio exclusive, Manesh R. Patel, MD, FACC, FAHA, FSCAI, provides his perspective on a few of the late-breaking clinical trials presented at the American Heart Association Scientific Sessions.

Researchers have identified lipid cutoffs that may indicate elevated risk for MI and stroke among young adults aged 20 to 39 years without a history of diabetes, according to findings published in European Journal of Preventive Cardiology.

The level of total cholesterol minus HDL and LDL was associated with progression of atherosclerosis, independently of traditional CV risk factors, according to data published in Circulation: Cardiovascular Imaging.

Vupanorsen (Ionis) for reduction of non-HDL in patients with hyperlipidemia already on statin therapy.

WASHINGTON — Treatment with vupanorsen, a novel antisense oligonucleotide targeting hepatic ANGPTL3, achieved modest reductions in non-HDL at 24 weeks at all doses studied, according to results of the TRANSLATE-TIMI 70 trial.

In an update on FDA approvals and late-breaking trials in lipid therapies, a speaker reviewed the current and future landscapes of LDL- and triglyceride-lowering therapies.

While rare, certain genetic and multifactorial causes of severe hypertriglyceridemia may warrant special considerations for diagnosis and treatment within their respective patient populations, a speaker reported.

Among patients with severe hypertriglyceridemia who underwent MRI proton density fat fraction, clinically meaningful hepatic steatosis appeared to be common, according to a presenter at the National Lipid Association Scientific Sessions.

Accurate and precise laboratory lipid measurements are important. As such, the National Lipid Association has released a new scientific statement on lipid measurements in the management of CVDs.

Much research is being conducted on novel therapeutics to reduce residual lipid-related risks, a speaker said at the National Lipid Association Scientific Sessions.